Establishing Rationale for the Clinical Development of Cell Therapy Products: Consensus between Risk and Benefit
- Author:
Seunghoon HAN
1
;
Hyeon Woo YIM
;
Hyunsuk JEONG
;
Suein CHOI
;
Sungpil HAN
Author Information
- Publication Type:REVIEW ARTICLE
- From:International Journal of Stem Cells 2023;16(1):16-26
- CountryRepublic of Korea
- Language:English
- Abstract: Despite long-term research achievements, the development of cell therapy (CT) products remains challenging. This is because the risks experienced by the subject and therapeutic effects in the clinical trial stage are unclear due to the various uncertainties of CT when administered to humans. Nevertheless, as autologous cell products for systemic administration have recently been approved for marketing, CT product development is accelerating, particularly in the field of unmet medical needs. The human experience of CT remains insufficient compared with other classes of pharmaceuticals, while there are countless products for clinical development. Therefore, for many sponsors, understanding the rationale of human application of an investigational product based on the consensus and improving the ability to apply it appropriately for CT are necessary. Thus, defining the level of evidence for safety and efficacy fundamentally required for initiating the clinical development and preparing it using a reliable method for CT. Furthermore, the expertise should be strengthened in the design of the first-in-human trial, such as the starting dose and dose-escalation plan, based on a sufficiently acceptable rationale. Cultivating development professionals with these skills will increase the opportunity for more candidates to enter the clinical development phase.
